Targeting ligand-gated ion channels in neurology and psychiatry: Is pharmacological promiscuity an obstacle or an opportunity?

BMC Pharmacology

Volumn 10, Issue , 2010, Pages

  Bianchi, Matt T ^a   Botzolakis, Emmanuel J ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; CENTRAL NERVOUS SYSTEM AGENTS; FLUOXETINE; GLYCINE RECEPTOR; ION CHANNEL; IONOTROPIC RECEPTOR; LIGAND GATED ION CHANNEL; METABOTROPIC RECEPTOR; NEUROTRANSMITTER RECEPTOR; NICOTINIC RECEPTOR; NORFLUOXETINE; SEROTONIN 3 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; LIGAND; SEROTONIN;

ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EFFECTIVENESS; DRUG DESIGN; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SPECIFICITY; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; HYPOTHESIS; MENTAL DISEASE; NEUROMODULATION; NEUROPHARMACOLOGY; PSYCHOPHARMACOLOGY; THEORY VALIDATION; BEHAVIOR; CHANNEL GATING; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFECT; METHODOLOGY; NEUROLOGY; PHYSIOLOGY; PSYCHIATRY;

BEHAVIOR; CENTRAL NERVOUS SYSTEM AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; ION CHANNEL GATING; ION CHANNELS; LIGANDS; MENTAL DISORDERS; NEUROLOGY; PSYCHIATRY; RECEPTORS, GABA-A; RECEPTORS, NEUROTRANSMITTER; SEROTONIN;

EID: 77950510228     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-10-3     Document Type: Article

References (39)

1. Mazzocchi F. Complexity in biology. Exceeding the limits of reductionism and determinism using complexity theory. EMBO Rep 2008, 9(1):10-14. 10.1038/sj.embor.7401147, 2246621, 18174892.
2. Nobeli I, Favia AD, Thornton JM. Protein promiscuity and its implications for biotechnology. Nat Biotechnol 2009, 27(2):157-167. 10.1038/nbt1519, 19204698.
3. Erickson RP. From "magic bullet" to "specially engineered shotgun loads": the new genetics and the need for individualized pharmacotherapy. Bioessays 1998, 20(8):683-685. 10.1002/(SICI)1521-1878(199808)20:8<683::AID-BIES12>3.0.CO;2-V, 9780843.
4. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004, 3(4):353-359. 10.1038/nrd1346, 15060530.
5. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, et al. Predicting new molecular targets for known drugs. Nature 2009, 462(7270):175-181. 10.1038/nature08506, 19881490.
6. Peterson RT. Chemical biology and the limits of reductionism. Nat Chem Biol 2008, 4(11):635-638. 10.1038/nchembio1108-635, 18936741.
7. Mencher SK, Wang LG. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin Pharmacol 2005, 5(1):3. 10.1186/1472-6904-5-3, 1090568, 15854222.
8. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005, 26(4):178-182. 10.1016/j.tips.2005.02.007, 15808341.
9. Schadt EE, Sachs A, Friend S. Embracing complexity, inching closer to reality. Sci STKE 2005, 2005(295):pe40. 10.1126/stke.2952005pe40, 16077086.
10. Li S, Armstrong CM, Bertin N, Ge H, Milstein S, Boxem M, Vidalain PO, Han JD, Chesneau A, Hao T, et al. A map of the interactome network of the metazoan C. elegans. Science 2004, 303(5657):540-543. 10.1126/science.1091403, 1698949, 14704431.
11. Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, Berriz GF, Gibbons FD, Dreze M, Ayivi-Guedehoussou N, et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 2005, 437(7062):1173-1178. 10.1038/nature04209, 16189514.
12. Yu H, Braun P, Yildirim MA, Lemmens I, Venkatesan K, Sahalie J, Hirozane-Kishikawa T, Gebreab F, Li N, Simonis N, et al. High-quality binary protein interaction map of the yeast interactome network. Science 2008, 322(5898):104-110. 10.1126/science.1158684, 2746753, 18719252.
13. Solt K, Forman SA. Correlating the clinical actions and molecular mechanisms of general anesthetics. Curr Opin Anaesthesiol 2007, 20(4):300-306. 10.1097/ACO.0b013e32816678a5, 17620835.
14. Eckenhoff RG. Promiscuous ligands and attractive cavities: how do the inhaled anesthetics work?. Mol Interv 2001, 1(5):258-268.
15. Bianchi MT, Pathmanathan J, Cash SS. From ion channels to complex networks: magic bullet versus magic shotgun approaches to anticonvulsant pharmacotherapy. Med Hypotheses 2009, 72(3):297-305. 10.1016/j.mehy.2008.09.049, 19046822.
16. Bianchi MT. Promiscuous modulation of ion channels by anti-psychotic and anti-dementia medications. Med Hypotheses 2009, 74(2):297-300. 10.1016/j.mehy.2009.09.003, 19786325.
17. Bianchi MT. Non-serotonin anti-depressant actions: direct ion channel modulation by SSRIs and the concept of single agent poly-pharmacy. Med Hypotheses 2008, 70(5):951-956.
18. Rammes G, Rupprecht R. Modulation of ligand-gated ion channels by antidepressants and antipsychotics. Mol Neurobiol 2007, 35(2):160-174. 10.1007/s12035-007-0006-1, 17917105.
19. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M. Drug-target network. Nat Biotechnol 2007, 25(10):1119-1126. 10.1038/nbt1338, 17921997.
20. Mehta AK, Ticku MK. An update on GABAA receptors. Brain Res Brain Res Rev 1999, 29(2-3):196-217. 10.1016/S0165-0173(98)00052-6, 10209232.
21. Lu T, Rubio ME, Trussell LO. Glycinergic transmission shaped by the corelease of GABA in a mammalian auditory synapse. Neuron 2008, 57(4):524-535. 10.1016/j.neuron.2007.12.010, 18304482.
22. Yang L, Sonner JM. The anesthetic-like effects of diverse compounds on wild-type and mutant gamma-aminobutyric acid type A and glycine receptors. Anesth Analg 2008, 106(3):838-845. 10.1213/ane.0b013e31816095bd, 18292428.
23. Colquhoun D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 1998, 125(5):924-947. 10.1038/sj.bjp.0702164, 1565672, 9846630.
24. Bianchi MT, Botzolakis EJ, Haas KF, Fisher JL, Macdonald RL. Microscopic kinetic determinants of macroscopic currents: insights from coupling and uncoupling of GABAA receptor desensitization and deactivation. J Physiol 2007, 584(Pt 3):769-787. 10.1113/jphysiol.2007.142364, 2276985, 17884921.
25. Bianchi MT, Macdonald RL. Neurosteroids shift partial agonist activation of GABA(A) receptor channels from low- to high-efficacy gating patterns. J Neurosci 2003, 23(34):10934-10943.
26. Feng HJ, Bianchi MT, Macdonald RL. Pentobarbital differentially modulates alpha1beta3delta and alpha1beta3gamma2L GABAA receptor currents. Mol Pharmacol 2004, 66(4):988-1003. 10.1124/mol.104.002543, 15247320.
27. Wohlfarth KM, Bianchi MT, Macdonald RL. Enhanced neurosteroid potentiation of ternary GABA(A) receptors containing the delta subunit. J Neurosci 2002, 22(5):1541-1549.
28. Liu F, Wan Q, Pristupa ZB, Yu XM, Wang YT, Niznik HB. Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. Nature 2000, 403(6767):274-280. 10.1038/35002014, 10659839.
29. Balasubramanian S, Teissere JA, Raju DV, Hall RA. Hetero-oligomerization between GABAA and GABAB receptors regulates GABAB receptor trafficking. J Biol Chem 2004, 279(18):18840-18850. 10.1074/jbc.M313470200, 14966130.
30. Boue-Grabot E, Toulme E, Emerit MB, Garret M. Subunit-specific coupling between gamma-aminobutyric acid type A and P2X2 receptor channels. J Biol Chem 2004, 279(50):52517-52525. 10.1074/jbc.M410223200, 15456793.
31. Miranda-Morales M, Garcia-Hernandez LM, Ochoa-Cortes F, Espinosa-Luna R, Naranjo-Rodriguez EB, Barajas-Lopez C. Cross-talking between 5-HT3 and GABAA receptors in cultured myenteric neurons. Synapse 2007, 61(9):732-740. 10.1002/syn.20411, 17568409.
32. Eisensamer B, Uhr M, Meyr S, Gimpl G, Deiml T, Rammes G, Lambert JJ, Zieglgansberger W, Holsboer F, Rupprecht R. Antidepressants and antipsychotic drugs colocalize with 5-HT3 receptors in raft-like domains. J Neurosci 2005, 25(44):10198-10206. 10.1523/JNEUROSCI.2460-05.2005, 16267227.
33. Robinson RT, Drafts BC, Fisher JL. Fluoxetine increases GABA(A) receptor activity through a novel modulatory site. J Pharmacol Exp Ther 2003, 304(3):978-984. 10.1124/jpet.102.044834, 12604672.
34. Stephenson VC, Heyding RA, Weaver DF. The "promiscuous drug concept" with applications to Alzheimer's disease. FEBS Lett 2005, 579(6):1338-1342. 10.1016/j.febslet.2005.01.019, 15733838.
35. Airan RD, Hu ES, Vijaykumar R, Roy M, Meltzer LA, Deisseroth K. Integration of light-controlled neuronal firing and fast circuit imaging. Curr Opin Neurobiol 2007, 17(5):587-592. 10.1016/j.conb.2007.11.003, 18093822.
36. Radhakrishnan ML, Tidor B. Specificity in molecular design: a physical framework for probing the determinants of binding specificity and promiscuity in a biological environment. J Phys Chem B 2007, 111(47):13419-13435. 10.1021/jp074285e, 17979267.
37. Deeds EJ, Ashenberg O, Gerardin J, Shakhnovich EI. Robust protein protein interactions in crowded cellular environments. Proc Natl Acad Sci USA 2007, 104(38):14952-14957. 10.1073/pnas.0702766104, 1986594, 17848524.
38. Azzaoui K, Hamon J, Faller B, Whitebread S, Jacoby E, Bender A, Jenkins JL, Urban L. Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem 2007, 2(6):874-880. 10.1002/cmdc.200700036, 17492703.
39. Bender A, Jenkins JL, Glick M, Deng Z, Nettles JH, Davies JW. "Bayes affinity fingerprints" improve retrieval rates in virtual screening and define orthogonal bioactivity space: when are multitarget drugs a feasible concept?. J Chem Inf Model 2006, 46(6):2445-2456. 10.1021/ci600197y, 17125186.